Related Experiment Videos

Msh2 deficiency enhances somatic Apc and p53 mutations in Apc+/-Msh2-/- mice

Kyoung-Jin Sohn1, Monica Choi, Jacquelin Song

  • 1Department of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada.

Carcinogenesis
|February 14, 2003
PubMed

Insights

Mice lacking Msh2 DNA repair show increased somatic mutations in Apc and p53 genes, leading to intestinal adenomas. This contrasts with Msh2-proficient mice where loss of heterozygosity is the primary driver.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cancer Research

Background:

  • Adenomatous polyposis coli (Apc) gene inactivation is crucial for intestinal adenoma development.
  • Loss of heterozygosity (LOH) is the established mechanism for Apc inactivation in Msh2-proficient Min mice.
  • Msh2 is vital for post-replicative DNA repair.

Purpose of the Study:

  • To investigate if Msh2 deficiency enhances somatic Apc and p53 mutations in Apc+/-Msh2-/- mice.
  • To compare mutation mechanisms in Msh2-proficient and Msh2-deficient intestinal adenomas.
  • To assess the impact of Msh2 deficiency on intestinal mucosa hypermutability.

Main Methods:

  • Comparative analysis of Apc and p53 mutations in intestinal adenomas and non-neoplastic mucosa.
  • Genotyping of Apc and Msh2 alleles in mouse models (Apc+/-Msh2+/+ vs. Apc+/-Msh2-/-).
  • Assessment of LOH and somatic mutation frequency in Apc and p53 genes.

Main Results:

  • Msh2 deficiency leads to a hypermutable state in intestinal mucosa, with increased somatic Apc mutations.
  • Adenomas in Apc+/-Msh2-/- mice exhibit a 2-fold higher rate of somatic Apc mutations and lack LOH.
  • Truncating Apc mutations are prevalent in Msh2-deficient adenomas, unlike in Min mice.
  • Somatic p53 mutations are frequent in Msh2-deficient adenomas, indicating widespread genomic instability.

Conclusions:

  • Somatic Apc mutations, not LOH, are the primary mechanism for Apc inactivation in Msh2-deficient intestinal adenomas.
  • Msh2 deficiency drives intestinal tumorigenesis through enhanced somatic mutations in critical cancer genes like Apc and p53.
  • Msh2 deficiency poses a risk for somatic mutations across various genomic sites, beyond simple repeats.

Related Concept Videos